Abstract 179P
Background
HCC is the fourth most common malignancy in China, and ranks second by mortality rate. Most patients have already reached advanced stage when diagnosed. TACE in combination with first-lined systematic therapy has been explored as an effective treatment for unresectable HCC. However, it has not been reported the safety and efficacy of Regorafenib combined with TACE, as a second-lined therapy. In this multicenter retrospective study, we preliminarily investigated the safety and efficacy of a combination with Regorafenib and TACE therapy in patients with unresectable HCC.
Methods
We reviewed the medical data of 38 patients with progression after prior treatment of Sorafenib and/or Lenvatinib from Jan 2019 to Apr 2020 at 4 tertiary centers in China. Patients were treated with TACE initially after enrollment. 5-7 days after the first TACE, patients started taking Regorafenib PO for 3 weeks on/1 week off. All patients were required to be followed up regularly and TACE was repeated as needed. The overall survival (OS), time to progression (TTP), progression-free survival (PFS), drugs safety, adverse events (AEs) were observed. OS was calculated from date of first TACE to death. TTP was calculated from date of first TACE to progression. Adverse events were evaluated by Clavien classification. Drugs safety was investigated according to CTCAE v4.03.
Results
Baseline patient characteristics are presented in the table Table: 179P
Baseline patient characteristics
Baseline characteristic | Total (n=38) |
Age (years) | 59.4±9.19 |
Sex, n (%) | |
Male | 32 (84.2%) |
ECOG, n (%) | |
0 | 21 (55.3%) |
1 | 13 (34.2%) |
2 | 4 (10.5%) |
BCLC, n (%) | |
B | 18 (47.4%) |
C | 20 (52.6%) |
Hepatitis, n (%) | |
HBV | 32 (84.2%) |
HCV | 2 (5.3%) |
No | 4 (10.5%) |
Maximum tumor size (cm) | 3.75 (2.5, 7.5) |
Tumor number, n (%) | |
1 | 4 (10.5%) |
≥2 | 34 (89.5%) |
AFP (μg/L) | 50.85 (6.64, 1210) |
Extrahepatic metastasis, n (%) | 13 (34.2%) |
Portal vein invasion, n (%) | 12(31.6%) |
Prior Local Therapy, n (%) | |
Surgery | 13 (34.2%) |
Ablation | 20 (52.6%) |
TACE | 36 (94.7%) |
Radiotherapy | 6 (15.8%) |
Follow-up, months(range) | 5.6 (1.7,17.0) |
Prior Systemic Therapy, n(%) Sorafenib Lenvatinib Lenvatinib Sequential to Sorafenib | 33 (86.8%) 1(2.6%) 4(10.5%) |
Conclusions
Regardless of the retrospective nature, the present study as the first up-to-date real-world evidence indicates that Regorafenib combined with TACE was clinically effective and tolerable in subsequent to prior systemic therapy for unresectable HCC. Additional prospective large-scale studies are required to further verify our conclusion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session
312P - Identification of neoantigen-specific T cell response and anti-tumour immunity in pancreatic cancer
Presenter: Xiaoxiao Du
Session: e-Poster Display Session